Literature DB >> 23784914

Arterial hypertension and cancer.

Alberto Milan1, Elisabetta Puglisi, Laura Ferrari, Giulia Bruno, Isabel Losano, Franco Veglio.   

Abstract

Arterial hypertension and cancer are two of the most important causes of mortality in the world; correlations between these two clinical entities are complex and various. Cancer therapy using old (e.g., mitotic spindle poisons) as well as new (e.g., monoclonal antibody) drugs may cause arterial hypertension through different mechanisms; sometimes the increase of blood pressure levels may be responsible for chemotherapy withdrawal. Among newer cancer therapies, drugs interacting with the VEGF (vascular endothelial growth factors) pathways are the most frequently involved in hypertension development. However, many retrospective studies have suggested a relationship between antihypertensive treatment and risk of cancer, raising vast public concern. The purposes of this brief review have then been to analyse the role of chemotherapy in the pathogenesis of hypertension, to summarize the general rules of arterial hypertension management in this field and finally to evaluate the effects of antihypertensive therapy on cancer disease.
© 2013 UICC.

Entities:  

Keywords:  anti VEGF drugs; antihypertensive therapies; arterial hypertension; cancer therapies

Mesh:

Substances:

Year:  2013        PMID: 23784914     DOI: 10.1002/ijc.28334

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  10 in total

Review 1.  Targeted Cancer Therapies and QT Interval Prolongation: Unveiling the Mechanisms Underlying Arrhythmic Complications and the Need for Risk Stratification Strategies.

Authors:  Rezarta Cuni; Iris Parrini; Riccardo Asteggiano; Maria Rosa Conte
Journal:  Clin Drug Investig       Date:  2017-02       Impact factor: 2.859

Review 2.  [Summary of the ESC position paper on cancer treatment and cardiovascular toxicity].

Authors:  J Hoog; S Achenbach
Journal:  Herz       Date:  2016-12       Impact factor: 1.443

3.  Chronic arterial hypertension impedes glioma growth: a multiparametric MRI study in the rat.

Authors:  Annelise Letourneur; Simon Roussel; Myriam Bernaudin; Fabien Fillesoye; Jérôme Toutain; Eric T MacKenzie; Edwige Petit; Omar Touzani; Samuel Valable
Journal:  Hypertens Res       Date:  2015-06-18       Impact factor: 3.872

Review 4.  From Molecular Mechanisms to Clinical Management of Antineoplastic Drug-Induced Cardiovascular Toxicity: A Translational Overview.

Authors:  Carlo Gabriele Tocchetti; Christian Cadeddu; Daniela Di Lisi; Saveria Femminò; Rosalinda Madonna; Donato Mele; Ines Monte; Giuseppina Novo; Claudia Penna; Alessia Pepe; Paolo Spallarossa; Gilda Varricchi; Concetta Zito; Pasquale Pagliaro; Giuseppe Mercuro
Journal:  Antioxid Redox Signal       Date:  2017-05-15       Impact factor: 8.401

Review 5.  Diagnosis, Treatment, and Prevention of Cardiovascular Toxicity Related to Anti-Cancer Treatment in Clinical Practice: An Opinion Paper from the Working Group on Cardio-Oncology of the Korean Society of Echocardiography.

Authors:  Hyungseop Kim; Woo-Baek Chung; Kyoung Im Cho; Bong-Joon Kim; Jeong-Sook Seo; Seong-Mi Park; Hak Jin Kim; Ju-Hee Lee; Eun Kyoung Kim; Ho-Joong Youn
Journal:  J Cardiovasc Ultrasound       Date:  2018-03-28

Review 6.  Metabolic syndrome and esophageal cancer risk: a systematic review and meta‑analysis.

Authors:  Jinjia Zhang; Huadong Wu; Rongying Wang
Journal:  Diabetol Metab Syndr       Date:  2021-01-19       Impact factor: 3.320

7.  Effects of Carfilzomib Therapy on Left Ventricular Function in Multiple Myeloma Patients.

Authors:  Giulia Mingrone; Anna Astarita; Lorenzo Airale; Ilaria Maffei; Marco Cesareo; Teresa Crea; Giulia Bruno; Dario Leone; Eleonora Avenatti; Cinzia Catarinella; Marco Salvini; Giusy Cetani; Francesca Gay; Sara Bringhen; Franco Veglio; Fabrizio Vallelonga; Alberto Milan
Journal:  Front Cardiovasc Med       Date:  2021-04-21

Review 8.  Risk Factors for the Comorbidity of Hypertension and Renal Cell Carcinoma in the Cardio-Oncologic Era and Treatment for Tumor-Induced Hypertension.

Authors:  Zhengqing Ba; Ying Xiao; Ming He; Dong Liu; Hao Wang; Hanyang Liang; Jiansong Yuan
Journal:  Front Cardiovasc Med       Date:  2022-02-17

9.  Renin-angiotensin inhibitors were associated with improving outcomes of hepatocellular carcinoma with primary hypertension after hepatectomy.

Authors:  Long-Hai Feng; Hui-Chuan Sun; Xiao-Dong Zhu; Shi-Zhe Zhang; Kang-Shuai Li; Xiao-Long Li; Yan Li; Zhao-You Tang
Journal:  Ann Transl Med       Date:  2019-12

10.  Prevalence and prognosis significance of cardiovascular disease in cancer patients: a population-based study.

Authors:  Dong Liu; Zhiqiang Ma; Jingang Yang; Min Zhao; Huiping Ao; Xiaodong Zheng; Qianfa Wen; Yuejin Yang; Jiangyun You; Shubin Qiao; Jiansong Yuan
Journal:  Aging (Albany NY)       Date:  2019-09-27       Impact factor: 5.682

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.